نتایج جستجو برای: paclitaxel

تعداد نتایج: 16677  

Journal: :Oncology 1997
G N Hortobagyi

Clinical trials to develop paclitaxel (Taxol)-containing combinations started in 1992 with several approaches to combine doxorubicin and paclitaxel. Schedule-dependent toxicity limited doses in the initial trials, although antitumor activity was high. More recently, a well-tolerated, highly effective doxorubicin/paclitaxel regimen was developed with the use of bolus anthracycline administration...

Nanotechnology has revolutionized diagnosis and treatment of cancers. Breast cancer is oneof the most prevalent cancers among women. Paclitaxel and hydroxyurea are important drugsin treatment of breast cancer but their use is limited due to a series of significant side effects.On the other hand, nanoliposomes are widely used as nanocarriers for targeted drug delivery.In this study, cytotoxic ef...

Journal: :Journal of pharmacological sciences 2012
Ken-Ichi Serizawa Kenji Yogo Ken Aizawa Yoshihito Tashiro Yoko Takahari Kaori Sekine Toshihiko Suzuki Nobuhiko Ishizuka Hideyuki Ishida

Paclitaxel-eluting stents dramatically reduce rates of in-stent restenosis; however, paclitaxel is known to lead to endothelial dysfunction. Protective effects of nicorandil on paclitaxel-induced endothelial dysfunction by examining flow-mediated dilation (FMD) were investigated in anesthetized rats. After 7-day osmotic infusion of paclitaxel (5 mg/kg per day), FMD was measured by high-resoluti...

Journal: :Proteomics. Clinical applications 2009
Yuan Tian Aik-Choon Tan Xiaer Sun Matthew T Olson Zhi Xie Natini Jinawath Daniel W Chan Ie-Ming Shih Zhen Zhang Hui Zhang

Paclitaxel has been widely used as an anti-mitotic agent in chemotherapy for a variety of cancers and adds substantial efficacy as the first-line chemotherapeutic regimen for ovarian cancers. However, the frequent occurrence of paclitaxel resistance limits its function in long-term management. Despite abundant clinical and cellular demonstration of paclitaxel resistant tumors, the molecular mec...

2015
Madappa N Kundranda Jiaxin Niu

Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities associated with the solvents used in the formulation of standard paclitaxel and to potentially improve efficacy. Nab-paclitaxel has demonstrated an advantage over solvent-based paclitaxel by being able to deliver a higher dose of paclit...

2015
George Dranitsaris Bo Yu Jennifer King Satyin Kaura Adams Zhang

BACKGROUND Paclitaxel and docetaxel are commonly used for metastatic breast cancer in the People's Republic of China. To improve the safety and efficacy of paclitaxel, an albumin-bound formulation (nab) is now available in the People's Republic of China (Abraxane(®)). To provide health economic data for the key stakeholders, a cost-utility analysis comparing nab-paclitaxel to docetaxel, both as...

2011
Yutaka Yamamoto Ichiro Kawano Hirotaka Iwase

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel formulation of paclitaxel that does not require solvents such as polyoxyethylated castor oil and ethanol. Use of these solvents has been associated with toxic response, including hypersensitivity reactions and prolonged sensory neuropathy, as well as a negative impact in relation to the therapeutic index of paclitaxel. nab-paclit...

2015
YU-PING DANG XIAO-YING YUAN RONG TIAN DONG-GUANG LI WEI LIU

Paclitaxel, isolated from Taxus brevifolia, is considered to be an efficacious agent against a wide spectrum of human cancers, including human cervical cancer. However, dose-limiting toxicity and high cost limit its clinical application. Curcumin, a nontoxic food additive, has been reported to improve paclitaxel chemotherapy in mouse models of cervical cancer. However, the underlying mechanisms...

2017
Kenji Tamura Kenichi Inoue Norikazu Masuda Shintaro Takao Masahiro Kashiwaba Yutaka Tokuda Hiroji Iwata Naohito Yamamoto Kenjiro Aogi Toshiaki Saeki Takahiro Nakayama Nobuaki Sato Tatsuya Toyama Takanori Ishida Hitoshi Arioka Mitsue Saito Shinji Ohno Hideko Yamauchi Kimito Yamada Junichiro Watanabe Hiroshi Ishiguro Yasuhiro Fujiwara

Weekly administration of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has been shown to be a safe and effective treatment for metastatic breast cancer (MBC) in clinical studies. We conducted a multicenter, randomized, open-label phase II study to compare the efficacy and safety of weekly nab-paclitaxel and docetaxel in Japanese patients with human epidermal growth factor receptor 2-ne...

Journal: :Molecular cancer therapeutics 2004
Zhenfeng Duan Katherine A Brakora Michael V Seiden

Ovarian cancer is currently the most lethal gynecologic malignancy in developed countries, and paclitaxel is a cornerstone in the treatment of this malignancy. Unfortunately, the efficacy of paclitaxel is limited by the development of drug resistance. Clinical paclitaxel resistance is often associated with ABCB1 (MDR1) overexpression, and in vitro paclitaxel resistance typically demonstrates ov...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید